# Pharmacokinetic Modeling And Stability

Model pharmacokinetics from the in-vitro release data to predict in-vivo plasma levels, then execute stability testing to establish shelf life.

## Inputs

- `in-vitro-release-data`: Measured release profile from dissolution
- `formulation-specification`: Final formulation composition and dimensions
- `drug-properties`: Pharmacokinetic parameters (clearance, volume of distribution, bioavailability)

## Outputs

- `pk-model-predictions`: Predicted plasma concentration vs time with therapeutic window overlay
- `stability-data`: Stability results at accelerated and long-term conditions with shelf-life determination
- `release-specification`: Final release specification with acceptance criteria for manufacturing QC

## Process

1. Build a compartmental PK model: one- or two-compartment depending on drug distribution. Input the in-vitro release rate as the absorption rate (with in-vitro/in-vivo correlation if available from prior formulations of the same drug). Simulate plasma concentration over the dosing interval.
2. Compare predicted plasma levels to the therapeutic window. If Cmax exceeds the toxic threshold, reduce burst release. If Cmin falls below the effective concentration before the next dose, increase the sustained release rate or shorten the dosing interval.
3. For long-acting injectables, apply an IVIVC (in-vitro/in-vivo correlation) level A if possible: point-to-point relationship between in-vitro dissolution and in-vivo absorption. This allows in-vitro release to serve as a surrogate for bioequivalence in future formulation changes.
4. Execute stability studies per ICH Q1A: long-term (25C/60%RH), accelerated (40C/75%RH), and intermediate if needed. Test at 0, 3, 6, 9, 12 months minimum. Measure drug content, degradation products, release profile, and appearance at each time point.
5. Determine shelf life from stability data: the time point at which the release profile first exceeds the specification limits at the long-term condition, with statistical analysis per ICH Q1E. The accelerated condition data supports interim shelf life claims while long-term data accumulates.

---

Copyright 2024-present The Wayfinder Trust. All rights reserved.
